Quoin Pharmaceuticals Ltd. ADR (QNRX)
NASDAQ: QNRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
QNRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $15.76M
- P/E (TTM)
- 7.45
- EPS (TTM)
- $0.44
- Dividend yield
- None
- 52-week range
- 3.18 – 23.50
- Day range
- 3.18 – 3.54
- Volume / Avg
- 11.31K / 541.26K
- Beta
- —
- Shares outstanding
- 4.80M
52-week range
QNRX stock today
Quoin Pharmaceuticals (QNRX) closed at $3.28 on Nov 20, down 2.35% (-$0.0791), versus the S&P 500's 3.70% decline. Trading was light, with 11.31K shares changing hands, about 2% of the average daily volume. Shares are 86.0% below their 52-week high of $23.50, set on Nov 25, 2025 and 3.1% above the 52-week low of $3.18, near the bottom of the past year's range.
QNRX is down 77.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 82.1%. Quoin Pharmaceuticals trades at 7.5x its trailing twelve-month earnings per share of $0.44.
Summary generated from market data by MetaCap's automated system. Methodology
About Quoin Pharmaceuticals
Company profileQuoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael Myers Ph.D.
- Headquarters
- Ashburn, VA
- Employees
- 4
- IPO year
- 2016
- Website
- quoinpharma.com
Financial highlights
Full financialsQuoin Pharmaceuticals reported a net loss of $15.8 million, compared with a loss of $9.0 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 |
| Growth | — | — | — | — | — |
| Net income | $-15.80M | $-8.96M | $-8.69M | $-9.38M | $-21.46M |
| EPS (diluted) | — | — | — | — | $-0.01 |
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$21.83+565.55%
- Strong buy 1
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.97 vs $-1.88
- Surprise
- +48.40%
QNRX news
All QNRX news- Quoin Pharmaceuticals, Ltd. Reports Third Quarter 2026 Financial ResultsNasdaq
- Quoin Pharmaceuticals’ Latest NETHERTON NOW Video Details the Life of a Family Living with Netherton SyndromeGlobeNewswire
- Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals to Announce Corporate Update and Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewswire
- Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and TherapyGlobeNewswire
- Quoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin DisorderNasdaqQNRX, ET
- Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin SyndromeGlobeNewswire
Quoin Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PBMPsyence Biomedical Ltd. | 2.97 | +3.85% | $15.80M | vs QNRX |
| ATOSAtossa Therapeutics Inc. | 1.60 | -8.86% | $15.92M | vs QNRX |
| LPCNLipocine Inc. | 1.48 | -1.33% | $16.39M | vs QNRX |
| CELUCelularity Inc. Class A | 0.463 | -1.05% | $15.02M | vs QNRX |
| SHPHShuttle Pharmaceuticals Holdings Inc. | 3.49 | -10.51% | $16.63M | vs QNRX |
| AKTXAkari Therapeutics plc ADS | 7.18 | +7.00% | $16.70M | vs QNRX |
| CNTXContext Therapeutics Inc. | 0.16 | -5.10% | $14.70M | vs QNRX |
| NCELNewcelX Ltd. | 2.54 | -5.58% | $14.67M | vs QNRX |
Indexes, lists and sector
Quoin Pharmaceuticals stock FAQ
What is Quoin Pharmaceuticals's stock price today?
QNRX last traded at $3.28 as of Nov 20, 4:00 PM EST, down 2.35% on the day. Prices are delayed at least 15 minutes.
Does Quoin Pharmaceuticals pay a dividend?
No. Quoin Pharmaceuticals does not currently pay a regular cash dividend.
What is QNRX's P/E ratio?
QNRX trades at a trailing P/E ratio of 7.45.
Who is Quoin Pharmaceuticals's CEO?
Dr. Michael Myers Ph.D. is the chief executive officer of Quoin Pharmaceuticals Ltd. ADR, which has about 4 employees.
Has QNRX ever split its stock?
Yes. The most recent QNRX stock split was a 1-for-35 split on Apr 9, 2025, one of 5 splits on record.
What is the QNRX 52-week high?
The 52-week high for QNRX is $23.50 and the 52-week low is $3.18. The stock is currently 86.0% below its high.